|
Immunizations
 H1N1 Provider Pre-Registration - Special Announcement
More information here
Posted On 8/19/2009
Novel H1N1 Influenza Vaccine information from CDC
CDC’s Advisory Committee on Immunization Practices (ACIP) met on July 29, 2009 to make recommendations on who should receive the new H1N1 vaccine when it becomes available, and to determine which groups of people should be prioritized if the vaccine is initially available in limited quantities.
The committee recommended that initial vaccination efforts focus on five key populations:
- All people 6 months through 24 years of age
- People who live with or care for children younger than 6 months of age
- All pregnant women
- Healthcare and emergency services personnel
- People aged 25 through 64 years who have health conditions associated with higher risk of medical complications from influenza.
Together, these key populations equal 159 million. Once the demand for vaccine for these prioritized groups has been met at the local level, programs and providers should begin vaccinating everyone from the ages of 25 through 64 years.
If vaccine is available in insufficient amounts for the initial priority groups, the following groups would be prioritized:
- Pregnant women
- People who live with or care for children younger than 6 months of age
- Healthcare and emergency service personnel with direct patient contact
- Children 6 months through 4 years of age
- Children 5 through 18 years of age who have chronic medical conditions.
Novel H1N1 vaccine supply and availability is projected to increase quickly over time, and vaccine should not be kept in reserve for later administration of the second dose.
The novel H1N1 vaccine is not intended to replace the seasonal flu vaccine – it is intended to be used along-side seasonal flu vaccine to protect people. It is anticipated that both vaccines can be administered on the same day.
There are many steps involved with producing a vaccine and we are committed to going forward with NIH, FDA, BARDA an the manufacturers of influenza vaccines, to see about developing full scale vaccine production. If things progress to full scale production, vaccine may be available as early as mid-October. The novel H1N1 vaccine will be made using the same process and facilities that are used to make the currently licensed seasonal influenza vaccines.
We are concerned with protecting our nation’s children from vaccine-preventable diseases like influenza and preventing any possible adverse events from vaccines. We expect that H1N1 will be available inn multiple formulations, including a formulation that does not contain the preservative thimerosal.
Posted on 8/10/2009
New Alerts
Vaccine Safety
Immunization Requirements
Flu Resources
MOBI-KS
|
